{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine the safety of related or unrelated allogeneic PBSCT using a preparative regimen of busulfan, melphalan and alemtuzumab. The primary safety endpoint is non-relapse mortality at day +100.","groups":[{"description":"Three drug regimen using busulfan, and melphalan, and alemtuzumab.\n\nBusulfan, and melphalan, and alemtuzumab: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).\n\nIntravenous melphalan 100 mg/m2 on day -3.\n\nIntravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.","id":"OG000","title":"Busulfan, and Melphalan, and Alemtuzumab"}],"populationDescription":"Data were collected but could not be analyzed. PI for this study has retired and any data that were gathered, are lost. No data are available for this assessment.","reportingStatus":"POSTED","timeFrame":"Day +100","title":"Number of Participants With Relapse-free Survival.","type":"SECONDARY"}